Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Final Results of a Multicenter Pilot Study Evaluating Brentuximab Vedotin with Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the Treatment of Aggressive Adult T-Cell Leukemia/Lymphoma

Christopher Dittus, Matthew Weinstock, Jeffrey A. Barnes, Jose Sandoval-Sus, Natalie S. Grover, Anne Beaven, Xianming Tan, Areej El-Jawahri, Shayna R Sarosiek, John Mark Sloan

Blood (2023) 142 (Supplement 1): 1692.

https://doi.org/10.1182/blood-2023-173822

Published: 2023

Journal Articles

High Risk Cytogenetic and Immunohistochemistry Findings in Monomorphic Post-Transplant Lymphoproliferative Disorder Following Solid Organ Transplant - a Single Center Experience

Timothy J Voorhees, MD, Natalie S Grover, MD, Jonathan Galeotti, MD MS, Nathan D Montgomery, MD, Dominic T. Moore, MPH, MS, Anne Beaven, MD, Christopher Dittus, DO

Blood (2019) 134 (Supplement_1): 2915.

https://doi.org/10.1182/blood-2019-126228

Published: 2019

Journal Articles

Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

Timothy J Voorhees, MD, Natalie S Grover, MD, Anne Beaven, MD, Steven I Park, MD, J. Kaitlin Morrison, PhD, Catherine Joyce Arago Cheng, BS, Spencer Laing, BA, Gianpietro Dotti, MD, Barbara Savoldo, MD PhD, Jonathan S Serody, MD

Blood (2019) 134 (Supplement_1): 3233.

https://doi.org/10.1182/blood-2019-122846

Published: 2019

Journal Articles

Clinical Responses to CAR.CD30-T Cells in Patients with CD30+ Lymphomas Relapsed after Multiple Treatments Including Brentuximab Vedotin

Blood (2018) 132 (Supplement 1): 681.

https://doi.org/10.1182/blood-2018-99-113534

Published: 2018

Journal Articles

Successful Treatment of Mature T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: The Largest Multicenter Retrospective Analysis

Neha Mehta-Shah, MD, Stephanie Teja, Yu Tao, MD, Amanda F. Cashen, MD, Anne Beaven, MD, Onder Alpdogan, MD, Pierluigi Porcu, MD, Mackenzie Wiggin, Kevin W Song, MD, Musa Alzahrani, Parastoo B. Dahi, MD, Alison J. Moskowitz, MD, Steven M. Horwitz, MD, Eric D. Jacobsen, MD

Blood (2017) 130 (Supplement 1): 4597.

https://doi.org/10.1182/blood.V130.Suppl_1.4597.4597

Published: 2017

Journal Articles

A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.

Cristina Gasparetto, MD, Michael Green, MD, Anandgopal Srinivasan, MDcal Student, Yubin Kang, MD, David A. Rizzieri, MD, Carlos Decastro, MD, Louis F. Diehl, MD, Anne Beaven, MD, Zighuo Li, PhD, Arati V. Rao, MD, Anderson Garrett, Sascha Tuchman, MD, Gwynn D. Long, MD

Blood (2015) 126 (23): 1857.

https://doi.org/10.1182/blood.V126.23.1857.1857

Published: 2015

Journal Articles

A Phase 1b Clinical Trial of Dacetuzumab in Combination with Rituximab and Gemcitabine: Multiple Responses Observed in Patients with Relapsed Diffuse Large B-Cell Lymphoma.

Andres Forero-Torres, MD, Nancy L Bartlett, MD, Sunita D Nasta, MD, Donald Northfelt, MD, Anne Beaven, MD, Han Myint, FRCP, FRCPath, Nancy C Whiting, PharmD, BCOP, Jonathan G Drachman, MD, Craig H Moskowitz, MD

Blood (2009) 114 (22): 586.

https://doi.org/10.1182/blood.V114.22.586.586

Published: 2009

Journal Articles

Early Pre/Post Fluoro-Deoxyglucose Positive Emission Tomography (PET) Does Not Predict Outcome of Patients Undergoing Hematopoietic Stem Cell Transplantation in Hodgkins Disease and Non-Hodgkins Lymphoma.

Jeanne Palmer, MD, Timothy Goggins, MD, Gloria Broadwater, Nelson J. Chao, MD, John Chute, MD, R. E. Coleman, MD, Keith M Sullivan, MD, Gwynn Long, MD, Cristina Gasparetto, MD, Anne Beaven, MD, David Rizzieri, MD

Blood (2008) 112 (11): 2180.

https://doi.org/10.1182/blood.V112.11.2180.2180

Published: 2008

Journal Articles

A Phase I Study of Bortezomib (Velcade ® ) Plus 90 yttrium Labeled Ibritumomab Tiuxetan (Zevalin ® ) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NHL)

Anne Beaven, MD, Thomas C. Shea, MD, Dominic T Moore, PhD, Tatyana Feldman, MD, Anastasia Ivanova, PhD, Madlyn Ferraro, RN, OCN, CCRC, Peggy Ford, RN, Judy Smith, RN, Andre Goy, MD

Blood (2008) 112 (11): 4944.

https://doi.org/10.1182/blood.V112.11.4944.4944

Published: 2008

NARROW

Final Results of a Multicenter Pilot Study Evaluating Brentuximab Vedotin with Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the Treatment of Aggressive Adult T-Cell Leukemia/Lymphoma

High Risk Cytogenetic and Immunohistochemistry Findings in Monomorphic Post-Transplant Lymphoproliferative Disorder Following Solid Organ Transplant - a Single Center Experience

Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

Clinical Responses to CAR.CD30-T Cells in Patients with CD30+ Lymphomas Relapsed after Multiple Treatments Including Brentuximab Vedotin

Successful Treatment of Mature T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: The Largest Multicenter Retrospective Analysis

A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.

A Phase 1b Clinical Trial of Dacetuzumab in Combination with Rituximab and Gemcitabine: Multiple Responses Observed in Patients with Relapsed Diffuse Large B-Cell Lymphoma.

Early Pre/Post Fluoro-Deoxyglucose Positive Emission Tomography (PET) Does Not Predict Outcome of Patients Undergoing Hematopoietic Stem Cell Transplantation in Hodgkins Disease and Non-Hodgkins Lymphoma.

A Phase I Study of Bortezomib (Velcade ® ) Plus 90 yttrium Labeled Ibritumomab Tiuxetan (Zevalin ® ) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NHL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only